Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07748169

An Observational Study of Patients With Dermatologic Disease

TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Vitiligo Alopecia Alopecia Areata Atopic Dermatitis Bacterial Infections Bacterial Infections and Mycoses Congenital, Hereditary, and Neonatal Diseases and Abnormalities Dermatitis Dermatitis, Atopic Genetic Diseases, Inborn Hair Diseases Hidradenitis Hidradenitis Suppurativa Hidradenitis Suppurativa (HS) Hypersensitivity Hypersensitivity, Immediate Hypopigmentation Hypotrichosis Immune System Diseases Infections Pigmentation Disorders Skin Diseases Skin Diseases, Bacterial Skin Diseases, Eczematous Skin Diseases, Genetic Skin Diseases, Infectious Skin and Connective Tissue Diseases Suppuration Sweat Gland Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Wake Forest University Health Science, Winston-Salem, North Carolina, United States

Loading trial locations.

About this study

TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them. TARGET-DERM+ is designed to develop a large, robust database of real-world data regarding the natural history, management, and health outcomes related to the care of DD of diverse etiologies and practice settings. The study is also designed to establish learning health networks focused on quality of care for patients with DD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult or pediatric participants managed for DD invited to participate OR a provider who treats patients with these conditions. Informed consent is required for all Engaged Cohort participants.
  • Adult or pediatric participants at the time of enrollment with a diagnosis of DD by ICD code or other relevant healthcare code as part of the EHR interface.

Exclusion criteria

  • Participant withdrew consent; Failure to complete activities as required per the cohort clarification letter.

Treatment and study plan

Primary outcomes

  1. To assess safety and effectiveness of DD treatments and treatments for complications of any dermatologic disease

    Time frame: 15 years

    The study will evaluate the characteristics of patients receiving various treatments, effectiveness of treatment, and medical events that develop while receiving treatment for DD

  2. To characterize the natural history of disease in patients with dermatologic disease from various etiologies

    Time frame: 15 years

    A detailed analysis of available demographics (age, race, sex, country of birth, insurance status), medications, co-morbidities, and medical history from sites across the US will inform the profile for this patient population.

  3. To establish learning health networks focused on quality of care for patients

    Time frame: 15 years

    Identify deficiencies and best practices in care of patients with DD.

    • Evaluate outcomes from targeted learning content in the management of patients with DD.

Secondary outcomes

  1. To evaluate provider management practices in the treatment of patients with DD

    Time frame: 15 years

    Health care provider type, clinic setting, reason for initiating/not initiating/adjusting dosing of treatments, reason for discontinuing/switching treatments, and monitoring outcomes on and off treatment, will be captured as available in the provided EHR and/or through linked data.

  2. To evaluate longitudinal and patient reported outcomes in DD

    Time frame: 15 years

    Longitudinal clinical outcomes and disease progression will be assessed. Self-reported patient health measures collect information directly from patients to measure physical, mental, and social health.

Study contacts

Contact information is provided by the study sponsor or research team.

Danisha Devane

CONTACT

[email protected]

9842340268

Lynda Lee Burch

CONTACT

[email protected]

9842340268

Sponsors and collaborators

Lead sponsor

Target PharmaSolutions, Inc.

Industry

Registry information

Acronym: TARGET-DERM+

Important dates

Study start
2026
Primary completion
2041
Study completion
2041
First posted
Aug 5, 2026
Registry last updated
Aug 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.